Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia

References

• HirschJAn anniversary for cancer chemotherapyJAMA2006296121518152017003400
   PubMed Web of Science ®Google Scholar
• GoodmanLSWintrobeMMNitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disordersJAMA1946132126132
   PubMed Web of Science ®Google Scholar
• OgawaMDifferentiation and proliferation of hematopoietic stem cellsBlood19938111284428538499622
   PubMed Web of Science ®Google Scholar
• SummersCRankinSMCondliffeAMSinghNPetersAMChilversERNeutrophil kinetics in health and diseaseTrends Immunol201031831832420620114
   PubMed Web of Science ®Google Scholar
• CrawfordJDaleDCLymanGHChemotherapy-induced neutropenia: risks, consequences, and new directions for its managementCancer2004100222823714716755
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Common Terminology Criteria for Adverse Advents v3.0 (CTCAE) [Internet]2015 Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdfAccessed August 9, 2006
   Google Scholar
• NesherLRolstonKVThe current spectrum of infection in cancer patients with chemotherapy related neutropeniaInfection201442151323975584
   PubMed Web of Science ®Google Scholar
• CaggianoVWeissRVRickertTSLinde-ZwirbleWTIncidence, cost, and mortality of neutropenia hospitalization associated with chemotherapyCancer200510391916192415751024
   PubMed Web of Science ®Google Scholar
• MichelsSLBarronRLReynoldsMWSmoyer TomicKYuJLymanGHCosts associated with febrile neutropenia in the USPharmacoeconomics201230980982322804805
   PubMed Web of Science ®Google Scholar
• SchillingMBParksCDeeterRGCosts and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective studyExp Ther Med20112585986622977589
   PubMed Web of Science ®Google Scholar
• NagataSTsuchiyaMAsanoSThe chromosomal gene structure and two mRNAs for human granulocyte colony-stimulating factorEMBO J1986535755812423327
   PubMedGoogle Scholar
• PlatzerEOezSWelteKHuman pluripotent hemopoietic colony stimulating factor: activities on human and murine cellsImmunobiology19861723–51851933492429
   PubMedGoogle Scholar
• SouzaLMBooneTCGabriloveJRecombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cellsScience1986232474661652420009
   PubMed Web of Science ®Google Scholar
• WelteKPlatzerELuLPurification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factorProc Natl Acad Sci U S A1985825152615303871951
   PubMed Web of Science ®Google Scholar
• DührsenUVillevalJLBoydJKannourakisGMorstynGMetcalfDEffects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patientsBlood1988726207420813264199
   PubMed Web of Science ®Google Scholar
• WelteKBonillaMAGillioAPRecombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primatesJ Exp Med198716549419483494094
   PubMed Web of Science ®Google Scholar
• IkebuchiKIhleJNHiraiYWongGGClarkSCOgawaMSynergistic factors for stem cell proliferation: further studies of the target stem cells and the mechanism of stimulation by interleukin-1, interleukin-6, and granulocyte colony-stimulating factorBlood1988726200720143264195
   PubMedGoogle Scholar
• IkebuchiKClarkSCIhleJNSouzaLMOgawaMGranulocyte colony-stimulating factor enhances interleukin 3-dependent proliferation of multipotential hemopoietic progenitorsProc Natl Acad Sci U S A19888510344534492453060
   PubMedGoogle Scholar
• MetcalfDNicolaNAProliferative effects of purified granulocyte colony-stimulating factor (G-CSF) on normal mouse hemopoietic cellsJ Cell Physiol198311621982066602806
   PubMedGoogle Scholar
• BronchudMHScarffeJHThatcherNPhase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancerBr J Cancer19875668098132829955
   PubMed Web of Science ®Google Scholar
• GabriloveJLJakubowskiAScherHEffect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urotheliumN Engl J Med198831822141414222452983
   PubMed Web of Science ®Google Scholar
• GabriloveJLJakubowskiAFainKPhase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urotheliumJ Clin Invest1988824145414612459163
   PubMed Web of Science ®Google Scholar
• MorstynGCampbellLSouzaLMEffect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapyLancet1988185876676722895212
   PubMed Web of Science ®Google Scholar
• LordBIWoolfordLBMolineuxGKinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF)Clin Cancer Res2001772085209011448927
   PubMed Web of Science ®Google Scholar
• JohnstonECrawfordJBlackwellSRandomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapyJ Clin Oncol200018132522252810893282
   PubMed Web of Science ®Google Scholar
• GreenMDKoelblHBaselgaJInternational Pegfilgrastim 749 Study GroupA randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapyAnn Oncol2003141293512488289
   PubMed Web of Science ®Google Scholar
• HoggattJPelusLMNew G-CSF agonists for neutropenia therapyExpert Opin Investig Drugs20142312135
   PubMed Web of Science ®Google Scholar
• Abdolzade-BavilACookseyBScheckermannCPegylated versus glycopegylated G-CSFs and their biochemical and physiological properties [abstract]Blood20131224851
   Web of Science ®Google Scholar
• MahlertFSchmidtKAllgaierHLiuPMüllerUDavid ShenWRational development of lipegfilgrastim, a novel long-acting granulocyte colony-stimulating factor, using glycopegylation technology [abstract]Blood20131224853
   Web of Science ®Google Scholar
• European Medicines Agency Product Information: Lonquex [Internet]2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002556/WC500148380.pdf
   Google Scholar
• BuchnerALammerichAAbdolzade-BavilAMullerUBiasPLipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteersCurr Med Res Opin201430122523253325251999
   PubMed Web of Science ®Google Scholar
• ArmstrongJKHempelGKolingSAntibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patientsCancer2007110110311117516438
   PubMed Web of Science ®Google Scholar
• RichterAWAkerblomEPolyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donorsInt Arch Allergy Appl Immunol198474136396706424
   PubMedGoogle Scholar
• BondarenkoIGladkovOAElsaesserRBuchnerABiasPEfficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapyBMC Cancer20131338623945072
   PubMed Web of Science ®Google Scholar
• BuchnerAElsasserRBiasPA randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapyBreast Cancer Res Treat2014148110711625261291
   PubMed Web of Science ®Google Scholar
• VolovatCBondarenkoIMGladkovOAEfficacy and safety of lipegfilgrastim in elderly patients with non-small-cell lung cancer receiving cisplatin/etoposide chemotherapyJ Geraitr Oncol20123Sup 1S97S98
   Google Scholar